Semaglutide for Post-Smoking Cessation Weight Management

NCT06173778 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether semaglutide, a medication, can help people who have quit smoking and are overweight or obese manage their weight.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 197 people Planned (estimated).

Who can join Ages 18–75 · all sexes Healthy volunteers accepted.

Timeline Started 2024-04 · est. completion 2026-08

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT06173778 ↗

Description as written by the study sponsor.

This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.

Treatments tested

semaglutide 2.4mg Drug

Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached
Placebo Drug

Non-active medication, self-administered
Nicotine Replacement Therapy (NRT, nicotine patch) Drug

Participants who smoke \>10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.
Brief Smoking Cessation Counseling Behavioral

Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.

Main thing measured	Change in Body Weight Percent
Sponsor	The University of Texas Health Science Center, Houston
Conditions studied	Obesity, Overweight, Cigarette Smoking
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06173778 ↗